40729_2019_191_MOESM2_ESM.docx (78.21 kB)
MOESM2 of Dental implants in immunocompromised patients: a systematic review and meta-analysis
journal contribution
posted on 2019-11-28, 05:06 authored by Fabian Duttenhoefer, Marc Fuessinger, Yasmin Beckmann, Rainer Schmelzeisen, Knut Groetz, Martin BoekerAdditional file 2. Detailed results table. (1) author, (2) publishing year, (3) study type, (4) medical condition (HIV infection, chemotherapy, transplantation, autoimmune disease, oral cancer / squamous cell carcinoma), (5) number of patients included in the study, (6) fraction of female and male patients, (7) age of the patients (median), (8) absolute number of placed implants, (9) absolute number of failed implants, (10) time of implantation after extraction, (11) time of loading, (11) maximum follow-up period, (12) survival rate of implants, (13) localization (mandible, maxilla), (14) generic therapy term (antiretroviral therapy, steroid containing medication, chemotherapy, immunosuppressive drugs), (15) applied drug, (16) duration of the applied therapy at the time of implantation, (17) underlying disease (Crohn’s disease, oral lichen planus, rheumatoid arthritis, scleroderma, Sjogren syndrome, dermato myositis, pemphigus vulgaris, polymyalgia rheumatica, systemic lupus erythematosus, oral cancer / squamous cell carcinoma), (18) CD4 cell count, (19) viral load, (20) prescribed antibiotic drug, (21) period in which the study was carried out, (22) type of effect estimate (relative risk, odds ratio, attributable risk/ excess risk, arcsine difference, standardized mean difference, weighted mean difference, hazard ratio), (23) value of effect estimate, (24) risk of bias assessment, (25) overall objectives of the study, (26) setting and/ or place of study, (27) additional information.